

# Edgar Marcelino de Carvalho

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3687466/publications.pdf>

Version: 2024-02-01

128  
papers

5,641  
citations

66343

42  
h-index

88630

70  
g-index

129  
all docs

129  
docs citations

129  
times ranked

3971  
citing authors

#	ARTICLE	IF	CITATIONS
1	Bladder dysfunction in human T cell lymphotropic virus infection: A prospective cohort study. PLoS Neglected Tropical Diseases, 2022, 16, e0009772.	3.0	0
2	Protection and Pathology in Leishmania braziliensis Infection. Pathogens, 2022, 11, 466.	2.8	4
3	Leishmania braziliensis causing human disease in Northeast Brazil presents loci with genotypes in long-term equilibrium. PLoS Neglected Tropical Diseases, 2022, 16, e0010390.	3.0	0
4	A Double-blind, Randomized Trial to Evaluate Miltefosine and Topical Granulocyte Macrophage Colony-stimulating Factor in the Treatment of Cutaneous Leishmaniasis Caused by <i>Leishmania braziliensis</i> in Brazil. Clinical Infectious Diseases, 2021, 73, e2465-e2469.	5.8	9
5	Inflammasome Activation by CD8+ T Cells from Patients with Cutaneous Leishmaniasis Caused by <i>Leishmania braziliensis</i> in the Immunopathogenesis of the Disease. Journal of Investigative Dermatology, 2021, 141, 209-213.e2.	0.7	10
6	Impaired Th1 Response Is Associated With Therapeutic Failure in Patients With Cutaneous Leishmaniasis Caused by <i>Leishmania braziliensis</i> . Journal of Infectious Diseases, 2021, 223, 527-535.	4.0	12
7	Association of miltefosine with granulocyte and macrophage colony-stimulating factor (GM-CSF) in the treatment of cutaneous leishmaniasis in the Amazon region: A randomized and controlled trial. International Journal of Infectious Diseases, 2021, 103, 358-363.	3.3	5
8	Inhibition of gamma-secretase activity without interfering in Notch signalling decreases inflammatory response in patients with cutaneous leishmaniasis. Emerging Microbes and Infections, 2021, 10, 1219-1226.	6.5	2
9	Phenotypic Characterization of CD4+ T Lymphocytes in Periportal Fibrosis Secondary to Schistosomiasis. Frontiers in Immunology, 2021, 12, 605235.	4.8	4
10	Influence of Obesity on Clinical Manifestations and Response to Therapy in Cutaneous Leishmaniasis Caused by <i>Leishmania braziliensis</i> . Clinical Infectious Diseases, 2021, 73, 1020-1026.	5.8	3
11	High Anti-Leishmania IgG Antibody Levels Are Associated With Severity of Mucosal Leishmaniasis. Frontiers in Cellular and Infection Microbiology, 2021, 11, 652956.	3.9	11
12	Anti-Leishmania IgG is a marker of disseminated leishmaniasis caused by <i>Leishmania braziliensis</i> . International Journal of Infectious Diseases, 2021, 106, 83-90.	3.3	9
13	The Influence of Infection by Different <i>Leishmania (Viannia) braziliensis</i> Isolates on the Pathogenesis of Disseminated Leishmaniasis. Frontiers in Cellular and Infection Microbiology, 2021, 11, 740278.	3.9	6
14	Blockade of TLR2 and TLR4 Attenuates Inflammatory Response and Parasite Load in Cutaneous Leishmaniasis. Frontiers in Immunology, 2021, 12, 706510.	4.8	11
15	Glyburide, a NLRP3 Inhibitor, Decreases Inflammatory Response and Is a Candidate to Reduce Pathology in <i>Leishmania braziliensis</i> Infection. Journal of Investigative Dermatology, 2020, 140, 246-249.e2.	0.7	24
16	Granzyme B Produced by Natural Killer Cells Enhances Inflammatory Response and Contributes to the Immunopathology of Cutaneous Leishmaniasis. Journal of Infectious Diseases, 2020, 221, 973-982.	4.0	30
17	Human CD8+ T Cells Release Extracellular Traps Co-Localized With Cytotoxic Vesicles That Are Associated With Lesion Progression and Severity in Human Leishmaniasis. Frontiers in Immunology, 2020, 11, 594581.	4.8	16
18	Evaluation of the Ability of Miltefosine Associated with Topical GM-CSF in Modulating the Immune Response of Patients with Cutaneous Leishmaniasis. Journal of Immunology Research, 2020, 2020, 1-9.	2.2	5

#	ARTICLE	IF	CITATIONS
19	Neurologic, clinical, and immunologic features in a cohort of HTLV-1 carriers with high proviral loads. <i>Journal of NeuroVirology</i> , 2020, 26, 520-529.	2.1	4
20	Diabetes Modifies the Clinic Presentation of Cutaneous Leishmaniasis. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa491.	0.9	6
21	Case Report: Unusual Presentation of Pharyngeal Mucosal Leishmaniasis due to <i>Leishmania (Viannia) braziliensis</i> . <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 1493-1495.	1.4	2
22	Impaired immunoregulatory network of the <sc>CD</sc>4 T lymphocytes in refractory asthma. <i>Clinical and Experimental Allergy</i> , 2019, 49, 644-654.	2.9	2
23	The Role of NK Cells in the Control of Viral Infection in HTLV-1 Carriers. <i>Journal of Immunology Research</i> , 2019, 2019, 1-9.	2.2	9
24	Variable gene expression and parasite load predict treatment outcome in cutaneous leishmaniasis. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	63
25	A Th2-Type Response Is Associated With Exuberant Lesions in Pregnant Women Infected With <i>Leishmania braziliensis</i> . <i>Journal of Infectious Diseases</i> , 2019, 219, 480-488.	4.0	5
26	Prevalence of Bowel Symptoms in Patients Infected with Human T-Lymphotropic type 1 Virus. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2019, 52, e20180486.	0.9	4
27	Onabotulinumtoxin type A improves lower urinary tract symptoms and quality of life in patients with human T cell lymphotropic virus type 1 associated overactive bladder. <i>Brazilian Journal of Infectious Diseases</i> , 2018, 22, 79-84.	0.6	3
28	IL-1 $\beta$ Production by Intermediate Monocytes Is Associated with Immunopathology in Cutaneous Leishmaniasis. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1107-1115.	0.7	52
29	Early Cutaneous Leishmaniasis Patients Infected With <i>Leishmania braziliensis</i> Express Increased Inflammatory Responses After Antimony Therapy. <i>Journal of Infectious Diseases</i> , 2018, 217, 840-850.	4.0	22
30	Impaired TNF, IL-1 $\beta$ , and IL-17 production and increased susceptibility to <i>Mycobacterium tuberculosis</i> infection in HTLV-1 infected individuals. <i>Tuberculosis</i> , 2018, 108, 35-40.	1.9	15
31	Susceptibility of dendritic cells from individuals with schistosomiasis to infection by <i>Leishmania braziliensis</i> . <i>Molecular Immunology</i> , 2018, 93, 173-183.	2.2	6
32	Early Suppression of Macrophage Gene Expression by <i>Leishmania braziliensis</i> . <i>Frontiers in Microbiology</i> , 2018, 9, 2464.	3.5	9
33	Local and systemic production of proinflammatory chemokines in the pathogenesis of HAM/TSP. <i>Cellular Immunology</i> , 2018, 334, 70-77.	3.0	9
34	Tamoxifen and meglumine antimoniate combined therapy in cutaneous leishmaniasis patients: a randomised trial. <i>Tropical Medicine and International Health</i> , 2018, 23, 936-942.	2.3	27
35	<i>Schistosoma mansoni</i> rSm29 Antigen Induces a Regulatory Phenotype on Dendritic Cells and Lymphocytes From Patients With Cutaneous Leishmaniasis. <i>Frontiers in Immunology</i> , 2018, 9, 3122.	4.8	12
36	CD45RO+ T Cells and T Cell Activation in the Long-Lasting Immunity after <i>Leishmania infantum</i> Infection. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 98, 875-882.	1.4	7

#	ARTICLE	IF	CITATIONS
37	The Elderly Respond to Antimony Therapy for Cutaneous Leishmaniasis Similarly to Young Patients but Have Severe Adverse Reactions. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 98, 1317-1324.	1.4	16
38	Association of Tuberculosis Status with Neurologic Disease and Immune Response in HTLV-1 Infection. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 1126-1133.	1.1	6
39	<i>Schistosoma mansoni</i> antigens alter activation markers and cytokine profile in lymphocytes of patients with asthma. <i>Acta Tropica</i> , 2017, 166, 268-279.	2.0	13
40	Prevalence and risk factors for Human T-Lymphotropic Virus Type 1 (HTLV-1) among maintenance hemodialysis patients. <i>BMC Nephrology</i> , 2017, 18, 64.	1.8	13
41	Fluconazole in the Treatment of Cutaneous Leishmaniasis Caused by <i>Leishmania braziliensis</i> : A Randomized Controlled Trial. <i>Clinical Infectious Diseases</i> , 2017, 64, 67-71.	5.8	55
42	Phenotypic and functional characteristics of HLA-DR+ neutrophils in Brazilians with cutaneous leishmaniasis. <i>Journal of Leukocyte Biology</i> , 2017, 101, 739-749.	3.3	25
43	In Vitro Immunomodulatory Activity of a Transition-State Analog Inhibitor of Human Purine Nucleoside Phosphorylase in Cutaneous Leishmaniasis. <i>Journal of Immunology Research</i> , 2017, 2017, 1-6.	2.2	3
44	CD8+ T cell cytotoxicity mediates pathology in the skin by inflammasome activation and IL-1 $\beta$ production. <i>PLoS Pathogens</i> , 2017, 13, e1006196.	4.7	160
45	Mucosal leishmaniasis: A Retrospective Study of 327 Cases from an Endemic Area of <i>Leishmania (Viannia) braziliensis</i> . <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 97, 761-766.	1.4	41
46	Oral Pentoxifylline Associated with Pentavalent Antimony: A Randomized Trial for Cutaneous Leishmaniasis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 96, 1155-1159.	1.4	29
47	Association of Sicca Syndrome with Proviral Load and Proinflammatory Cytokines in HTLV-1 Infection. <i>Journal of Immunology Research</i> , 2016, 2016, 1-6.	2.2	20
48	Insulin-like growth factor-I serum levels and their biological effects on <i>Leishmania</i> isolates from different clinical forms of American tegumentary leishmaniasis. <i>Parasites and Vectors</i> , 2016, 9, 335.	2.5	6
49	The gp63 Gene Cluster Is Highly Polymorphic in Natural <i>Leishmania (Viannia) braziliensis</i> Populations, but Functional Sites Are Conserved. <i>PLoS ONE</i> , 2016, 11, e0163284.	2.5	14
50	Impairment of the humoral and CD4 + T cell responses in HTLV-1-infected individuals immunized with tetanus toxoid. <i>Human Immunology</i> , 2016, 77, 674-681.	2.4	2
51	HCV/HTLV coinfection: Does HTLV-1 interfere in the natural history of HCV-related diseases?. <i>Journal of Medical Virology</i> , 2016, 88, 1967-1972.	5.0	10
52	Immunologic Markers of Protection in <i>Leishmania (Viannia) braziliensis</i> Infection: A 5-Year Cohort Study. <i>Journal of Infectious Diseases</i> , 2016, 214, 570-576.	4.0	26
53	Effects of Physiotherapy in the Treatment of Neurogenic Bladder in Patients Infected With Human T-Lymphotropic Virus 1. <i>Urology</i> , 2016, 89, 33-39.	1.0	8
54	Author Reply. <i>Urology</i> , 2016, 89, 39.	1.0	0

#	ARTICLE	IF	CITATIONS
55	Characterization of Neutrophil Function in Human Cutaneous Leishmaniasis Caused by <i>Leishmania braziliensis</i> . <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0004715.	3.0	30
56	Atypical Manifestations of Cutaneous Leishmaniasis in a Region Endemic for <i>Leishmania braziliensis</i> : Clinical, Immunological and Parasitological Aspects. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0005100.	3.0	54
57	The Role of Nitric Oxide and Reactive Oxygen Species in the Killing of <i>Leishmania braziliensis</i> by Monocytes from Patients with Cutaneous Leishmaniasis. <i>PLoS ONE</i> , 2016, 11, e0148084.	2.5	144
58	Protective and Pathological Functions of CD8 <sup>+</sup> T Cells in <i>Leishmania braziliensis</i> Infection. <i>Infection and Immunity</i> , 2015, 83, 898-906.	2.2	97
59	Interleukin 10â€œDominant Immune Response and Increased Risk of Cutaneous Leishmaniasis After Natural Exposure to <i>Lutzomyia intermedia</i> Sand Flies. <i>Journal of Infectious Diseases</i> , 2015, 212, 157-165.	4.0	21
60	Treatment of Disseminated Leishmaniasis With Liposomal Amphotericin B. <i>Clinical Infectious Diseases</i> , 2015, 61, 945-949.	5.8	49
61	Age Modifies the Immunologic Response and Clinical Presentation of American Tegumentary Leishmaniasis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 92, 1173-1177.	1.4	18
62	Neurological Manifestations in Human T-Cell Lymphotropic Virus Type 1 (HTLV-1)â€œInfected Individuals Without HTLV-1â€œAssociated Myelopathy/Tropical Spastic Paraparesis: A Longitudinal Cohort Study. <i>Clinical Infectious Diseases</i> , 2015, 61, 49-56.	5.8	70
63	Role of Urine Neutrophil Gelatinase-Associated Lipocalin in the Early Diagnosis of Amphotericin B-Induced Acute Kidney Injury. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6913-6921.	3.2	20
64	Tr-1â€œLike CD4 <sup>+</sup> CD25 <sup>+</sup> CD127 <sup>+</sup> /lowFOXP3 <sup>+</sup> Cells Are the Main Source of Interleukin 10 in Patients With Cutaneous Leishmaniasis Due to <i>Leishmania braziliensis</i> . <i>Journal of Infectious Diseases</i> , 2015, 211, 708-718.	4.0	29
65	Intermediate Monocytes Contribute to Pathologic Immune Response in <i>Leishmania braziliensis</i> Infections. <i>Journal of Infectious Diseases</i> , 2015, 211, 274-282.	4.0	62
66	Genomic Profiling of Human <i>Leishmania braziliensis</i> Lesions Identifies Transcriptional Modules Associated with Cutaneous Immunopathology. <i>Journal of Investigative Dermatology</i> , 2015, 135, 94-101.	0.7	130
67	Comparative analysis of the tissue inflammatory response in human cutaneous and disseminated leishmaniasis. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2014, 109, 202-209.	1.6	24
68	The use of botulinum toxin type A in the treatment of HTLV-1-associated overactive bladder refractory to conventional therapy. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2014, 47, 528-532.	0.9	5
69	Functional Activity of Monocytes and Macrophages in HTLV-1 Infected Subjects. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3399.	3.0	15
70	Forecasting Temporal Dynamics of Cutaneous Leishmaniasis in Northeast Brazil. <i>PLoS Neglected Tropical Diseases</i> , 2014, 8, e3283.	3.0	20
71	Comment: seroprevalence of HTLV-1/2 among blood donors in the state of MaranhÃ£o Brazilâ€œSee paper by Viana GM et al. on pages 50-3. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2014, 36, 12-13.	0.7	2
72	The role of inflammatory and anti-inflammatory cytokines in the pathogenesis of human tegumentary leishmaniasis. <i>Cytokine</i> , 2014, 66, 127-132.	3.2	105

#	ARTICLE	IF	CITATIONS
73	Human Classical Monocytes Control the Intracellular Stage of <i>Leishmania braziliensis</i> by Reactive Oxygen Species. <i>Journal of Infectious Diseases</i> , 2014, 209, 1288-1296.	4.0	99
74	Clinical and Immunological Outcome in Cutaneous Leishmaniasis Patients Treated with Pentoxifylline. <i>American Journal of Tropical Medicine and Hygiene</i> , 2014, 90, 617-620.	1.4	42
75	Immunologic response and memory T cells in subjects cured of tegumentary leishmaniasis. <i>BMC Infectious Diseases</i> , 2013, 13, 529.	2.9	21
76	IL-17 Mediates Immunopathology in the Absence of IL-10 Following <i>Leishmania major</i> Infection. <i>PLoS Pathogens</i> , 2013, 9, e1003243.	4.7	144
77	CD8+ T cells in situ in different clinical forms of human cutaneous leishmaniasis. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2013, 46, 728-734.	0.9	15
78	Association between urinary symptoms and quality of life in HTLV-1 infected subjects without myelopathy. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2013, 39, 861-866.	1.5	17
79	Impaired Lymphocyte Profile in Schistosomiasis Patients with Periportal Fibrosis. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-8.	3.3	5
80	IFN- $\gamma$ Production to <i>Leishmania</i> Antigen Supplements the <i>Leishmania</i> Skin Test in Identifying Exposure to <i>L. braziliensis</i> Infection. <i>PLoS Neglected Tropical Diseases</i> , 2012, 6, e1947.	3.0	30
81	Association between an Emerging Disseminated form of Leishmaniasis and <i>Leishmania (Viannia) braziliensis</i> Strain Polymorphisms. <i>Journal of Clinical Microbiology</i> , 2012, 50, 4028-4034.	3.9	66
82	Protective and pathologic immune responses in human tegumentary leishmaniasis. <i>Frontiers in Immunology</i> , 2012, 3, 301.	4.8	86
83	A proposed new clinical staging system for patients with mucosal leishmaniasis. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 2012, 106, 376-381.	1.8	38
84	Immunological and viral features in patients with overactive bladder associated with human T-cell lymphotropic virus type 1 infection. <i>Journal of Medical Virology</i> , 2012, 84, 1809-1817.	5.0	26
85	Macrophages participate in host protection and the disease pathology associated with <i>Leishmania braziliensis</i> infection. <i>BMC Infectious Diseases</i> , 2012, 12, 75.	2.9	67
86	Immunopathogenesis and neurological manifestations associated to HTLV-1 infection. <i>Revista Da Sociedade Brasileira De Medicina Tropical</i> , 2012, 45, 545-552.	0.9	24
87	Clinical manifestations in individuals with recent diagnosis of HTLV type I infection. <i>Journal of Clinical Virology</i> , 2011, 51, 54-58.	3.1	48
88	Evaluation of the Microbicidal Activity and Cytokines/Chemokines Profile Released by Neutrophils from HTLV-1 Infected Individuals. <i>Scandinavian Journal of Immunology</i> , 2011, 74, 310-317.	2.7	9
89	Immunological and viral features in patients with overactive bladder indicate an early stage of myelopathy. <i>Retrovirology</i> , 2011, 8, .	2.0	1
90	Serial Quantitative PCR Assay for Detection, Species Discrimination, and Quantification of <i>Leishmania</i> spp. in Human Samples. <i>Journal of Clinical Microbiology</i> , 2011, 49, 3892-3904.	3.9	169

#	ARTICLE	IF	CITATIONS
91	Anthelmintic Therapy and Antimony in Cutaneous Leishmaniasis: A Randomized, Double-Blind, Placebo-Controlled Trial in Patients Co-Infected with Helminths and <i>Leishmania braziliensis</i> . <i>American Journal of Tropical Medicine and Hygiene</i> , 2011, 84, 551-555.	1.4	30
92	Miltefosine in the Treatment of Cutaneous Leishmaniasis Caused by <i>Leishmania braziliensis</i> in Brazil: A Randomized and Controlled Trial. <i>PLoS Neglected Tropical Diseases</i> , 2010, 4, e912.	3.0	185
93	Prevalence of Erectile Dysfunction in HTLV-1 Infected Patients and Its Association With Overactive Bladder. <i>Urology</i> , 2010, 75, 1100-1103.	1.0	39
94	Interleukin 17 Production among Patients with American Cutaneous Leishmaniasis. <i>Journal of Infectious Diseases</i> , 2009, 200, 75-78.	4.0	120
95	Association of Treatment of American Cutaneous Leishmaniasis Prior to Ulcer Development with High Rate of Failure in Northeastern Brazil. <i>American Journal of Tropical Medicine and Hygiene</i> , 2009, 80, 574-579.	1.4	68
96	Association of treatment of American cutaneous leishmaniasis prior to ulcer development with high rate of failure in northeastern Brazil. <i>American Journal of Tropical Medicine and Hygiene</i> , 2009, 80, 574-9.	1.4	47
97	Pentoxifylline down modulate in vitro T cell responses and attenuate pathology in <i>Leishmania</i> and HTLV-I infections. <i>International Immunopharmacology</i> , 2008, 8, 1344-1353.	3.8	18
98	Clinical Manifestations Associated with HTLV Type I Infection: A Cross-Sectional Study. <i>AIDS Research and Human Retroviruses</i> , 2007, 23, 365-371.	1.1	71
99	Microbiological and Immunological Features of Oral Candidiasis. <i>Microbiology and Immunology</i> , 2007, 51, 713-719.	1.4	33
100	Mucosal leishmaniasis: epidemiological and clinical aspects. <i>Brazilian Journal of Otorhinolaryngology</i> , 2007, 73, 843-847.	1.0	96
101	Urinary Symptoms Associated with Human T-Cell Lymphotropic Virus Type I Infection: Evidence of Urinary Manifestations in Large Group of HTLV-I Carriers. <i>Urology</i> , 2007, 69, 813-818.	1.0	52
102	Oral Pentoxifylline Combined with Pentavalent Antimony: A Randomized Trial for Mucosal Leishmaniasis. <i>Clinical Infectious Diseases</i> , 2007, 44, 788-793.	5.8	124
103	Influence of Helminth Infections on the Clinical Course of and Immune Response to <i>Leishmania braziliensis</i> Cutaneous Leishmaniasis. <i>Journal of Infectious Diseases</i> , 2007, 195, 142-148.	4.0	74
104	Urinary and sexual manifestations of patients infected by HTLV-I. <i>Clinics</i> , 2007, 62, 191-196.	1.5	35
105	The cause of urinary symptoms among Human T Lymphotropic Virus Type I (HTLV-I) infected patients: a cross sectional study. <i>BMC Infectious Diseases</i> , 2007, 7, 15.	2.9	21
106	Modulation of T Cell Responses in HTLV-1 Carriers and in Patients with Myelopathy Associated with HTLV-1. <i>NeuroImmunoModulation</i> , 2006, 13, 145-151.	1.8	28
107	Activated inflammatory T cells correlate with lesion size in human cutaneous leishmaniasis. <i>Immunology Letters</i> , 2005, 101, 226-230.	2.5	145
108	Decreased In Situ Expression of Interleukin-10 Receptor Is Correlated with the Exacerbated Inflammatory and Cytotoxic Responses Observed in Mucosal Leishmaniasis. <i>Infection and Immunity</i> , 2005, 73, 7853-7859.	2.2	185

#	ARTICLE	IF	CITATIONS
109	SUCCESSFUL TREATMENT OF REFRACTORY CUTANEOUS LEISHMANIASIS WITH GM-CSF AND ANTIMONIALS. American Journal of Tropical Medicine and Hygiene, 2005, 73, 79-81.	1.4	40
110	Familial aggregation of mucosal leishmaniasis in northeast Brazil. American Journal of Tropical Medicine and Hygiene, 2005, 73, 69-73.	1.4	11
111	Successful treatment of refractory cutaneous leishmaniasis with GM-CSF and antimonials. American Journal of Tropical Medicine and Hygiene, 2005, 73, 79-81.	1.4	21
112	Schistosoma mansoni infection modulates the immune response against allergic and auto-immune diseases. Memorias Do Instituto Oswaldo Cruz, 2004, 99, 27-32.	1.6	57
113	Antimony plus Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor Applied Topically in Low Doses Enhances Healing of Cutaneous Leishmaniasis Ulcers: A Randomized, Double-Blind, Placebo-Controlled Study. Journal of Infectious Diseases, 2004, 190, 1793-1796.	4.0	48
114	Impaired T Helper 2 Response to Aeroallergen in Helminth-Infected Patients with Asthma. Journal of Infectious Diseases, 2004, 190, 1797-1803.	4.0	106
115	Exacerbated inflammatory cellular immune response characteristics of HAM/TSP is observed in a large proportion of HTLV-I asymptomatic carriers. BMC Infectious Diseases, 2004, 4, 7.	2.9	85
116	Disseminated Leishmaniasis: A New and Emerging Form of Leishmaniasis Observed in Northeastern Brazil. Journal of Infectious Diseases, 2002, 186, 1829-1834.	4.0	154
117	Association between Mite Allergen (Der p 1, Der f 1, Blo t 5) Levels and Microscopic Identification of Mites or Skin Prick Test Results in Asthmatic Subjects. International Archives of Allergy and Immunology, 2002, 129, 237-241.	2.1	10
118	Up-Regulation of Th1-Type Responses in Mucosal Leishmaniasis Patients. Infection and Immunity, 2002, 70, 6734-6740.	2.2	306
119	Failure of Early Treatment of Cutaneous Leishmaniasis in Preventing the Development of an Ulcer. Clinical Infectious Diseases, 2002, 34, e69-e73.	5.8	86
120	HTLV-1 decreases Th2 type of immune response in patients with strongyloidiasis. Parasite Immunology, 2001, 23, 503-507.	1.5	163
121	Cytokine Profile and Immunomodulation in Asymptomatic Human T-Lymphotropic Virus Type 1-Infected Blood Donors. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 27, 1-6.	2.1	93
122	Variation of Cytokine Patterns Related to Therapeutic Response in Diffuse Cutaneous Leishmaniasis. Experimental Parasitology, 1996, 84, 188-194.	1.2	56
123	Evidence of a T helper type 2 activation in human schistosomiasis. European Journal of Immunology, 1996, 26, 1399-1403.	2.9	113
124	LEISHMANIASIS RECIDIVA CUTIS IN AMERICAN CUTANEOUS LEISHMANIASIS. International Journal of Dermatology, 1993, 32, 802-805.	1.0	30
125	Basidiobolomycosis: A Case Report. Pediatric Dermatology, 1991, 8, 325-328.	0.9	24
126	Parasite-specific humoral responses in different clinical forms of strongyloidiasis. Transactions of the Royal Society of Tropical Medicine and Hygiene, 1987, 81, 149-150.	1.8	14

#	ARTICLE	IF	CITATIONS
127	Selection of a Skin Test Antigen for American Visceral Leishmaniasis *. American Journal of Tropical Medicine and Hygiene, 1986, 35, 79-85.	1.4	141
128	High Continuous Antimony Therapy in Two Patients with Unresponsive Mucosal Leishmaniasis. American Journal of Tropical Medicine and Hygiene, 1985, 34, 710-713.	1.4	44